Celgene

CELG

Delayed Nasdaq Other stock markets 21:00:00 20/11/2019 GMT			5-day change	1st Jan Change
108.2 ^USD	+0.10%		-1.97%	+68.89%

2023	Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	CI
2021	Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	CI

Celgene Is Reportedly In Talks To Acquire Juno Therapeutics

January 16, 2018 at 05:00 am

Celgene Corporation (NasdaqGS:CELG) is in talks to buy Juno Therapeutics, Inc. (NasdaqGS:JUNO), according to the Wall Street Journal.

Latest news about Celgene

Sutro Biopharma, Inc. Receives a Notice of Termination from Celgene Corporation	14/06/23	CI
Biocon Limited, Biocon Pharma Limited and Biocon Pharma Inc. Enters into A Confidential Settlement Agreement with Celgene Corporation	08/09/21	CI
Celgene Corporation Will Grant Sun Pharmaceutical Industries Limited A License to Celgene's Patents Required to Manufacture and Sell Certain Limited Quantity	22/06/21	CI
Celgene Corporation Issues Notice of Redemption of Notes	22/02/21	CI
Bristol-Myers Squibb Company and Celgene Corporation Announce Tender Offers for an Aggregate Purchase Price of Up to $4.0 Billion	04/02/21	CI
Ikena Oncology, Inc. announced that it has received $120 million in funding from a group of investors	04/01/21	CI
Amgen : Signs Licensing Agreement With Medicines Development for Global Health	22/12/20	MT
Bristol Myers Squibb : Q3 Results Beat Estimates; Raises 2020 EPS Outlook	05/11/20	MT
Silverback Therapeutics, Inc. announced that it has received $84.999996 million in funding from a group of investors	22/09/20	CI
Silverback Therapeutics, Inc. announced that it expects to receive $84.999996 million in funding from a group of investors	21/09/20	CI
Agios Pharmaceuticals, Inc. Provides Update on 2016 Collaboration Agreement with Celgene	25/03/20	CI
Silverback Therapeutics, Inc. announced that it has received $68.400013 million in funding from a group of investors	10/03/20	CI
Pulmonary Fibrosis Foundation Launches Industry Consortium to Identify Biomarkers in Pulmonary Fibrosis	04/03/20	CI
DISH Network : Democratic lawmaker presses antitrust enforcers on company ties, settlements	08/01/20	RE
Galecto, Inc. acquired PharmAkea, Inc. from Bay City Capital LLC and Celgene Corporation for $17.4 million	06/01/20	CI
GNS Healthcare, Inc. announced that it has received $28 million in funding from Cigna Ventures, Amgen Ventures, Celgene Corporation, Echo Health Ventures, Alexandria Venture Investments, LLC, Merck Global Health Innovation Fund, LLC, and another investor	06/01/20	CI
More drugmakers hike U.S. prices as new year begins	01/01/20	RE
Dealmakers eye cross-border M&A recovery as mega mergers roll on	31/12/19	RE
Oncorus, Inc. announced that it has received $89.6 million in funding from a group of investors	19/12/19	CI
Amgen raises 2019 profit, sales view after buying Celgene psoriasis drug	21/11/19	RE
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Growth	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P TMI Index	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from INDUSTRIALS	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P 500 Value	21/11/19	CI
Celgene Corporation(NasdaqGM:CELG) dropped from S&P Global 1200	21/11/19	CI

Celgene Corporation specializes in the design, development, and sale of products for treating cancer and immune system disorders. Net sales break down by product family as follows: - therapeutic products (99.9%); - other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development. Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).

Sector

More about the company

Celgene

Equities

CELG

Celgene Is Reportedly In Talks To Acquire Juno Therapeutics

Latest news about Celgene

Chart Celgene

Company Profile